IGF1 and breast carcinoma: For instance, WISP2 may suppress EMT in breast cancer [10,36,37,38], on the other hand WISP2 silencing promotes a stem-like cell phenotype [11] and the loss of the IGF1 and EGF mitogenic effect in ER-α positive breast cancer cells [39,40].